SEARCH FOR ARTICLES ON PERSONALIZED PSYCHIATRY ON PUBMED:
LINKS TO FULL TEXT ARTICLES
Lally J, Gaughran F, Timms P, Curran SR. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharmgenomics Pers Med. 2016 Nov 7;9:117-129. (Added: 16th January 2017)
EAP CB. Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs. Dialogues Clin Neurosci. 2016 Sep;18(3):313-322. (Added: 16th January 2017)
Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K. Optimization of Clonazepam Therapy Adjusted to Patient’s CYP3A Status and NAT2 Genotype. Int J Neuropsychopharmacol. 2016 Dec 30;19(12) (Added:16th January 2017)
Perlis RH. Abandoning personalization to get to precision in the pharmacotherapy of depression. World Psychiatry. 2016 Oct;15(3):228-235.(Added: 16th January 2017)
Demyttenaere K. Taking the depressed “person” into account before moving into personalized or precision medicine. World Psychiatry. 2016 Oct;15(3):236-237 (Added: 16th January 2017)
Santacana M, Arias B, Mitjans M, Bonillo A, Montoro M, Rosado S, Guillamat R, Vallès V, Pérez V, Forero CG, Fullana MA. Predicting Response Trajectories during Cognitive-Behavioural Therapy for Panic Disorder: No Association with the BDNF Gene or Childhood Maltreatment. PLoS One. 2016 Jun 29;11 (Added: 16th January 2017)
Lv X, Si T, Wang G, Wang H, Liu Q, Hu C, Wang J, Su Y, Huang Y, Jiang H, Yu X. The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol. BMC Psychiatry. 2016 Jul 15;16:240. (Added: 16th January 2017)
Fraguas D, Díaz-Caneja CM, State MW, O’Donovan MC, Gur RE, Arango C. Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance. Psychol Med. 2017 Jan;47(2):193-197. (Added: 16th January 2017)
Murck H, Laughren T, Lamers F, Picard R, Walther S, Goff D, Sainati S. Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):26S-40S (Added: 23rd July 2015)
Caldirola D, Perna G. Is there a role for pharmacogenetics in the treatment of panic disorder? Pharmacogenomics, in press (Added: 21 June 2015)
Murck H, Laughren T, Lamers F, Picard R, Walther S, Goff D, Sainati S. Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):26S-40S. (Added: 1 June 2015)
Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat. 2015 Mar 31;11:875-88. (Added: 21 May 2015)
Karstoft KI, Galatzer-Levy IR, Statnikov A, Li Z, Shalev AY; Jerusalem Trauma Outreach and Prevention Study (J-TOPS) group. Bridging a translational gap: using machine learning to improve the prediction of PTSD. BMC Psychiatry. 2015 Mar 16;15:30. (Added: 21 May 2015)
Murck H, Laughren T, Lamers F, Picard R, Walther S, Goff D, Sainati S. Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):26S-40S. (Added: 21 May 2015)
McMahon FJ. Prediction of treatment outcomes in psychiatry–where do we stand ? Dialogues Clin Neurosci. 2014 Dec;16(4):455-64. (added 21 may 2015)
Pouget JG, Shams TA, Tiwari AK, Müller DJ. Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci. 2014 Dec;16(4):555-66. (added: 21 may 2015)
Emmett MR, Kroes RA, Moskal JR, Conrad CA, Priebe W, Laezza F, Meyer-Baese A, Nilsson CL.Integrative biological analysis for neuropsychopharmacology. Neuropsychopharmacology. 2014 Jan;39(1):5-23. (added: 20 Feb 2015)
Ozomaro U, Wahlestedt C, Nemeroff CB: Personalized medicine in psychiatry: problems and promises. BMC Med 2013; 11: 132.
Alda M. Personalized psychiatry: many questions, fewer answers. J Psychiatry Neurosci. Nov 2013; 38(6): 363–365.
Ozomaro U, Wahlestedt C, Nemeroff CB: Personalized medicine and psychiatry: dream or reality. psychiatric times, 9 oct 2013.
McGorry P, Keshavan M, Goldstone S, Amminger P, Allott K, Berk M, Lavoie S, Pantelis C, Yung A, Wood S, Hickie I. Biomarkers and clinical staging in psychiatry. World Psychiatry. 2014 Oct;13:211-23.
Li A, Meyre D. Jumping on the Train of Personalized Medicine: A Primer for Non-Geneticist Clinicians: Part 1. Fundamental Concepts in Molecular Genetics. Curr Psychiatry Rev. 2014 May;10:91-100.
Li A, Meyre D. Jumping on the Train of Personalized Medicine: A Primer for Non-Geneticist Clinicians: Part 2. Fundamental Concepts in Genetic Epidemiology. Curr Psychiatry Rev. 2014 May;10:101-117.
Li A, Meyre D. Jumping on the Train of Personalized Medicine: A Primer for Non-Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area. Curr Psychiatry Rev. 2014 May;10:118-132.
Villeneuve S, Brisson D, Marchant NL, Gaudet D. The potential applications of Apolipoprotein E in personalized medicine. Front Aging Neurosci. 2014 Jul 8;6:154.
Zajkowska ZE, Englund A, Zunszain PA. Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response. Pharmacogenomics. 2014 Apr;15(5):687-98.
Bakker JM, Lieverse R, Menne-Lothmann C, Viechtbauer W, Pishva E, Kenis G, Geschwind N, Peeters F, van Os J, Wichers M. Therapygenetics in mindfulness-based cognitive therapy: do genes have an impact on therapy-induced change in real-life positive affective experiences? Transl Psychiatry. 2014 Apr 22;4:e384.
Simmons LA, Wolever RQ, Bechard EM, Snyderman R. Patient engagement as a risk factor in personalized health care: a systematic review of the literature on chronic disease. Genome Med. 2014 Feb 26;6:16.
Karlawish J, Green RC. Minding the aging brain: are we ready for personalized medicine? Am J Psychiatry. 2014 Feb;171:137-9.
DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA, Lorenzo-Luaces L.The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS One. 2014 Jan 8;9(1):e83875
Bragazzi NL. Rethinking psychiatry with OMICS science in the age of personalized P5 medicine: ready for psychiatome? Philos Ethics Humanit Med. 2013 Jul 12;8:4.
Mehta D, Klengel T, Conneely KN, Smith AK, Altmann A, Pace TW, Rex-Haffner M, Loeschner A, Gonik M, Mercer KB, Bradley B, Müller-Myhsok B, Ressler KJ, Binder EB. Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8302-7.
Guest PC, Martins-de-Souza D, Schwarz E, Rahmoune H, Alsaif M, Tomasik J, Turck CW, Bahn S. Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Med. 2013 Mar 26;5(3):25.
McMahon FJ, Insel TR. Pharmacogenomics and personalized medicine in neuropsychiatry. Neuron. 2012 Jun 7;74(5):773-6.
Chapman BP, Roberts B, Duberstein P. Personality and longevity: knowns, unknowns, and implications for public health and personalized medicine. J Aging Res. 2011;2011: 759170.
Simon GE, Perlis RH.Personalized Medicine for Depression: Can We Match Patients with Treatments? Am J Psychiatry 2012; 167:1445-1455.
Hamburg MA, Collins FS. The Path to Personalized Medicine. N Engl J Med 2010; 363:301-304.